

~~Sub A2~~

1. A therapeutic agent for hypercalcemic crisis comprising, as an active ingredient, a substance capable of inhibiting the binding between parathyroid hormone related protein (PTHrP) and a receptor thereof.
2. The therapeutic agent for hypercalcemic crisis according to claim 1, wherein the substance is an antagonist against a PTHrP receptor.
3. The therapeutic agent for hypercalcemic crisis according to claim 1, wherein the substance is an anti-PTHrP antibody.
4. The therapeutic agent for hypercalcemic crisis according to claim 1, wherein the substance is a fragment of an anti-PTHrP antibody and/or a modified form of the fragment.
5. The therapeutic agent for hypercalcemic crisis according to claim 3 or 4, wherein the antibody is a humanized or chimeric antibody.
6. The therapeutic agent for hypercalcemic crisis according to claim 5, wherein the humanized antibody is humanized #23-57-137-1 antibody.
7. The therapeutic agent for hypercalcemic crisis according to claim 3 or 4, wherein the antibody is of monoclonal type.
8. The therapeutic agent for hypercalcemic crisis according to any one of claims 1 to 7, wherein the hypercalcemic crisis is hypercalcemic crisis associated with malignant tumor.